TMCI
Get informed when a big investor buys or sells
+ FollowOvervalued by 145% based on the discounted cash flow analysis.
| Market cap | $224.46 Million |
|---|---|
| Enterprise Value | $228.47 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.93 |
| Beta | 1.11 |
| Outstanding Shares | 64,592,681 |
| P/E Ratio | -3.66 |
|---|---|
| PEG | -28.59 |
| Price to Sales | 1.13 |
| Price to Book Ratio | 3.4 |
| Enterprise Value to Revenue | 1.1 |
| Enterprise Value to EBIT | -4.01 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.18 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 646.63% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 56.35%▲ 0.00% |
|---|---|
| Total Invested | $48.30M▼ 44.99% |
| Investors Holding | 116▼ 2.00% |
No data
Based in Ponte Vedra, FL, Treace Medical Concepts, Inc. is a privately-held medical device company focused on advancing the standard of care for the surgical management of bunion deformities. The Company’s patented Lapiplasty® 3D Bunion ...